Propranolol to treat hemangiomas of infancy: Safety and side effect recognition

JAMA Dermatology

Volumn 149, Issue 4, 2013, Pages 485-486

  Dyer, Jonathan A ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

BRADYCARDIA; BRONCHOSPASM; CHILD SAFETY; CLINICAL PROTOCOL; COUGHING; DRUG MONITORING; DRUG SAFETY; FOLLOW UP; HEART ARRHYTHMIA; HEMANGIOMA; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INFANT DISEASE; MEDICAL RECORD REVIEW; NOTE; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; STRIDOR; STUDY DESIGN; TREATMENT DURATION; WHEEZING; DRUG TOXICITY;

DRUG TOXICITY; HUMANS; PROPRANOLOL;

MLCS; MLOWN;

EID: 84876825549     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.1163     Document Type: Note

References (4)

1. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl JMed. 2008; 358(24):2649-2651. (Pubitemid 351831393)
2. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013;131(1):99-108.
3. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013; 131(1):128-140.
4. Kwon E-KM, Joachim S, Siegel DH, Drolet BA, Holland K. Retrospective review of adverse effects from propranolol in infants. JAMA Dermatol. 2013; 149(4):484-485.